February 1960
Angiology;Feb1960 Part 2, Vol. 11 Issue 1, p55
Academic Journal
Focuses on the therapeutic action of monoamine oxidase inhibitors. Involvement of serotonin in various biological processes; Importance of serotonin in the etiology of mental disease; Potential value of a group of drugs in diseases of the heart and circulation.


Related Articles

  • Treatment Considerations for Depression in Patients with Significant Medical Comorbidity. McCoy, David M. // Journal of Family Practice;Dec1996 Supplement, Vol. 43 Issue 6, pS35 

    In addition to being a strong psychological stressor in itself, medical illness is associated with risk factors that predispose patients to develop coexisting depression. Patients with conditions such as cancer, cardiovascular disease, and neurologic disorders are particularly prone to...

  • Linezolid and Serotonergic Drug Interactions: A Retrospective Survey. Taylor, Jeremy J.; Wilson, John W.; Estes, Lynn L. // Clinical Infectious Diseases;7/15/2006, Vol. 43 Issue 2, p180 

    Background. Linezolid is a reversible, nonselective monoamine oxidase inhibitor. There are currently 11 published case reports of serotonin syndrome being associated with linezolid and selective serotonin reuptake inhibitors (SSRIs). Controversy exists regarding whether linezolid and SSRIs can...

  • Fluoxetine vs Amitriptyline in the Treatment of Depressed Out-patients. Laakmann, G.; Blaschke, D.; Engel, R.; Schwarz, A. // British Journal of Psychiatry;Sep88 Supplement, p64 

    The article presents a comparison of fluoxetine and amitriptyline in the treatment of depressed outpatients. It is posed that as a result of various research in mental depression in recent years, therapeutic alternatives for the treatment of depressive illnesses have significantly increased....

  • The Role of Serotonin Reuptake Inhibitors in the Treatment of Psychiatric Illness: An Update. Diaz, David R.; Poor, Maria C. // Annals of the American Psychotherapy Association;Fall2009, Vol. 12 Issue 3, p45 

    The article offers an update on the uses of selective serotonin reuptake inhibitors (SSRIs) in the treatment of psychiatric disorders. Since their introduction in 1987, SSRIs have replaced monoamine oxidase inhibitors and tricyclic antidepressants because of their easier titration and favorable...

  • Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys. Gatch, Michael B.; Negus, S. Stevens; Mello, Nancy K. // Psychopharmacology;1998, Vol. 135 Issue 1, p99 

    Abstract Cocaine, which non-selectively blocks the reuptake of the monoamines serotonin, dopamine and norepinephrine, produces weak antinociceptive effects and increases the antinociceptive effects of low- to intermediate-efficacy mu opioid agonists in rhesus monkeys. In the present study, the...

  • monoamine oxidase inhibitor.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1485 

    An encyclopedia entry for "monoamine oxidase inhibitor," is presented.

  • A switch mechanism between locomotion and mouthing implicated in sensitization to quinpirole in rats. Culver, K. E.; Rosenfeld, J. M.; Szechtman, H. // Psychopharmacology;2000, Vol. 151 Issue 2/3, p202 

    Abstract Rationale: Chronic treatment with the monoamine oxidase inhibitor (MAOI) clorgyline, blocks locomotor sensitization to the D2/D3 dopamine agonist quinpirole. It is unknown whether this blockade occurs via inhibition of the MAO enzyme or by another mechanism. Objectives: While clorgyline...

  • Catecholaminergic Strategies for the Treatment of Major Depression. Tremblay, Philippe; Blier, Pierre // Current Drug Targets;Feb2006, Vol. 7 Issue 2, p149 

    Although the selective serotonin reuptake inhibitors have become the first line medications for the treatment of depression, drugs primarily targeting the norepinephrine (NE) and/or the dopamine catecholaminergic systems are also effective. These include selective NE reuptake inhibitors, such as...

  • Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study. Risinger, Robert; Bhagwagar, Zubin; Luo, Feng; Cahir, Matthew; Miler, Laura; Mendonza, Anisha; Meyer, Jeffrey; Zheng, Ming; Hayes, Wendy // Psychopharmacology;Jun2014, Vol. 231 Issue 11, p2299 

    Rationale: BMS-820836, a novel triple monoamine reuptake inhibitor, is an experimental monotherapy for sufferers of major depressive disorder who have had an inadequate response to an existing antidepressant treatment. Objectives: This study was conducted to evaluate the safety and tolerability,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics